lycxll
Lv7
4910 积分
2020-09-07 加入
-
PARP抑制剂不良反应管理的中国专家共识(2021年版)
2年前
已完结
-
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
2年前
已完结
-
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
2年前
已完结
-
An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer
2年前
已完结
-
IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial
3年前
已完结
-
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
3年前
已完结
-
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
3年前
已完结
-
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
3年前
已完结
-
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
3年前
已完结
-
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
3年前
已完结